Hot Flashes

 

Hot flashes are caused by hormonal changes that interfere with your body’s ability to lower its temperature. If you’ve been treated for breast cancer or prostate cancer, your hormone levels have been affected, and there is a good chance that you will experience hot flashes at some point.

You’ll know you are having a hot flash because your face and upper body will get hot, red, and sweaty. Your heart will beat faster, dilating your blood vessels. This circulates more blood, which causes more heat. Your sweat glands then give off more perspiration in an effort to cool your body.

Sometimes chemotherapy causes sudden menopause (known as chemotherapy-induced menopause). This can bring on hot flashes. In addition, hormonal treatment of breast cancer with drugs, including tamoxifen, Arimidex® (anastrozole), or Femara® (letrozole) can also cause hot flashes. Men who are being treated with hormonal therapy for prostate cancer can also experience hot flashes. Lupron® and Eligard® (leuprolide), Zoladex® (goserelin), Trelstar® (triptorelin pamoate), and Vantas (histrelin)® are hormone-blocking medications that can cause hot flashes.

Tips for Managing Hot Flashes

  • Dress in layers of cotton clothing—daytime clothing and sleepwear.
  • Keep your home or workplace at a cool temperature.
  • Keep ice water handy.
  • Take a cool shower.
  • Try deep-breathing exercises.
  • Consider acupuncture or yoga.
  • Talk to your doctor about the medications Neurontin® (gabapentin), Effexor-XR® (venlafaxine), or Paxil® (paroxetine), or other drugs in the family of agents called SSRIs.
This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Cancer News
REFILE: Komen charity under microscope for funding, science

February 8, 2012 — NEW YORK (Reuters) - The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fund-raising dollars it spends on grants to scientists working to understand the causes and develop effective new treatments for the disease.

US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

US consumers want tougher probe of engineered salmon

February 8, 2012 — WASHINGTON (Reuters) - Three U.S. consumer groups petitioned the Food and Drug Administration on Tuesday to subject a new genetically engineered salmon to a more rigorous review process than is now in place before the fish can be approved as safe to eat.

Select news items provided by Reuters Health